Journals of Gerontology Series A: Biological Sciences and Medical Sciences Large Type Edition
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frisoli, A.
Right arrow Articles by Szejnfeld, V. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frisoli, A., Jr.,
Right arrow Articles by Szejnfeld, V. L.
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:648-653 (2005)
© 2005 The Gerontological Society of America


RAPID COMMUNICATION

The Effect of Nandrolone Decanoate on Bone Mineral Density, Muscle Mass, and Hemoglobin Levels in Elderly Women With Osteoporosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Alberto Frisoli, Jr.,1, Paulo H. M. Chaves3, Marcelo Medeiros Pinheiro2 and Vera Lucia Szejnfeld2

1 Geriatric and Gerontology Division
2 Rheumatology Division, Department of Medicine, Federal University of São Paulo, Brazil.
3 Center on Aging and Health, Departments of Medicine and Epidemiology, Johns Hopkins University, Baltimore, Maryland.

Abstract

Methods. In a randomized, double-blind, placebo-controlled clinical trial, we evaluated the effect of a 2-year treatment with nandrolone decanoate (ND) on bone mineral density (BMD) of lumbar spine, femoral neck, and trochanter and on vertebral fracture rate, muscle mass, and hemoglobin levels. Sixty-five osteoporotic women older than 70 years were studied. Thirty-two patients received injections of 50 mg ND, and 33 received placebos every 3 weeks. All patients received 500 mg calcium tablets daily.

Results. Compared to baseline, ND increased the BMD of the lumbar spine (3.4% ± 6.0 and 3.7% ± 7.4; p <.05) and femoral neck (4.1% ± 7.3 and 4.7% ± 8.0; p <.05) after 1 and 2 years, respectively. The BMD of trochanter increased significantly only after the first year (4.8% ± 9.3, p <.05). Compared to the placebo group, the ND group presented with significantly increased BMD of the trochanter and neck. ND significantly reduced incidence of new vertebral fractures (21% vs 43% in the placebo group; p <.05). ND showed a significant statistical increase in lean body mass after the first (6.2% ± 5.8; p <.01) and second years (11.9% ± 29.2; p <.01). In addition, a 2-year treatment with ND significantly increased hemoglobin levels compared to baseline (14.3%; p <.01) and placebo (p <.01).

Conclusions. ND increased BMD, hemoglobin levels, and muscle mass, and reduced the vertebral fracture rate of elderly osteoporotic women.




This article has been cited by other articles:


Home page
EndocrinologyHome page
S. T. Page, B. T. Marck, J. M. Tolliver, and A. M. Matsumoto
Tissue Selectivity of the Anabolic Steroid, 19-Nor-4-Androstenediol-3{beta},17{beta}-Diol in Male Sprague Dawley Rats: Selective Stimulation of Muscle Mass and Bone Mineral Density Relative to Prostate Mass
Endocrinology, April 1, 2008; 149(4): 1987 - 1993.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
All GSA journals The Gerontologist
Journals of Gerontology Series B: Psychological Sciences and Social Sciences
Copyright © 2005 by The Gerontological Society of America.